HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Unpicking the combination lock for mutant BRAF and RAS melanomas.

Abstract
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
AuthorsBissan Al-Lazikani, Paul Workman
JournalCancer discovery (Cancer Discov) Vol. 3 Issue 1 Pg. 14-9 (Jan 2013) ISSN: 2159-8290 [Electronic] United States
PMID23319765 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Comment)
Chemical References
  • Antineoplastic Agents
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • ras Proteins
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage)
  • Humans
  • Melanoma (drug therapy)
  • Proto-Oncogene Proteins B-raf (genetics)
  • ras Proteins (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: